BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.
Location: United States, Pennsylvania, Philadelphia
Employees: 11-50
Total raised: $21M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Venture fo... | venturefor... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.09.2012 | - | $21M | - |
Mentions in press and media 24
| Date | Title | Description | Source |
| 08.02.2019 | Rutgers scientists form immuno-oncology biotech to de... | Raymond Birge There are thousands of immuno-oncology therapies in the global pipeline, and... | endpts.com... |
| 01.03.2016 | BioMotiv announces new startup: Anti-cancer drug developer Z... | The new potential product, developed by researchers out of Rutgers and SUNY Upstate, is providing a ... | medcitynew... |
| 04.05.2015 | Heart experts from Cleveland Clinic and Case Western team up... | BioMotiv is the for-profit affiliate of University Hospitals’ Harrington Project, a $250 million ini... | medcitynew... |
| 25.02.2015 | AstraZeneca and Orca Pharmaceuticals announce research colla... | AstraZeneca and Orca Pharmaceuticals announce research collaboration 25-02-2015 AstraZeneca and Or... | cambridgen... |
| 18.06.2014 | Biotech startup developing prostate cancer treatment is rais... | A research team led by Michael Ohlmeyer, an associate professor of structural and chemical biology a... | medcitynew... |
| 19.02.2014 | BioAtla-BioMotiv licensing deal results in new biotech start... | Consistent with BioMotiv’s business model, the new venture will manage development of the antibody t... | medcitynew... |
| 09.09.2013 | Biotech accelerator BioMotiv, NYU unveil a new spinoff for i... | With funding from BioMotiv and NYU’s Innovation Venture Fund, Orca is working toward achieving proof... | medcitynew... |
| 12.08.2013 | Biotech accelerator BioMotiv gets a $20M commitment from new... | BioMotiv CEO Baiju Shah A week after Cleveland's nascent biotech accelerator BioMotiv bumped its fi... | fiercebiot... |
| 05.08.2013 | BioMotiv Secures $25M in Additional Capital | CLEVELAND, OH, >> Click here for more funding data on BioMotiv >> To export BioMotiv... | vcnewsdail... |
| 05.08.2013 | With $46M in tow, accelerator/investor BioMotiv puts to work... | The non-profit components of the Harrington Project award grant support and resources to physician-s... | medcitynew... |
Show more